NASDAQ · CLDX
Celldex Therapeutics, Inc.
$29.89+$0.23 (+0.78%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.78% below the high.
Loading market information…
OSL · PCIB.OL · NOK
Stock price, earnings
Quote as of Apr 23, 2026, 02:25 PM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
PCI Biotech Holding ASA’s quoted price sits in the lower half of its reported 52-week range, 96.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PCI Biotech Holding ASA’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is focused on pioneering and bringing to market innovative treatments for cancer. At the core of their operations is the proprietary photochemical internalization (PCI) technology platform. The company's development pipeline features several distinct therapeutic strategies: fimaCHEM, a novel approach to chemotherapeutic cancer treatment; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is currently in Phase I clinical studies; and fimaNAc, a delivery system for nucleic acid therapeutics, presently in its pre-clinical phase. Furthermore, they provide Amphinex, a photosensitizer known as fimaporfin. PCI Biotech actively participates in joint research endeavors with partners such as Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$29.89+$0.23 (+0.78%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.78% below the high.
A$2.26-A$0.06 (-2.59%)
Mesoblast Limited’s quoted price sits in the lower half of its reported 52-week range, 31.72% below the high.
$10.87+$0.02 (+0.18%)
Monte Rosa Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.82% below the high.
NOK 10.44-NOK 0.10 (-0.95%)
Circio Holding ASA’s quoted price sits in the upper half of its reported 52-week range, 33.5% below the high.
$3.52-$0.02 (-0.56%)
Galectin Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.63% below the high.
NOK 8.02+NOK 0.26 (+3.35%)
IDEX Biometrics ASA’s quoted price sits in the upper half of its reported 52-week range, 37.34% below the high.
NOK 7.74+NOK 0.24 (+3.2%)
Lytix Biopharma AS’s quoted price sits in the lower half of its reported 52-week range, 34.96% below the high.
$0.11+$0.01 (+10.0%)
CASI Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.86% below the high.
